

Category

Best Incubator, Accelerator, Equity

General Information**Program/Fund Name ***

Cross-Border Impact Ventures

Corporate Name *

Cross-Border Impact Ventures

Date of Creation *

2021-12-10

Indications *

N/A

words remaining :

499

Therapeutic Areas *

N/A

words remaining :

499

*Kindly clearly label your files with company name and asset name.

Attached Files:

- [CBIV Fund II Short Deck 2025_05192025.pdf](#)

History of the development of the fund / Incubators

(please be as specific as possible in your description; limit 500 words)

Founded in 2021, Cross-Border Impact Ventures (CBIV) was created by Annie Thériault and Donna Parr with the financial and institutional support of Toronto-based non-profit Grand Challenges Canada (GCC), before it spun out of GCC into a standalone private impact fund. GCC is one of the country's largest impact-first investors and supports innovators in low- and middle-income countries and Canada to seed and transition to scale their Bold Ideas with Big Impact®. CBIV combines GCC's world class expertise in health and impact modelling, and Thériault and Parr's years of experience working in impact investing, venture capital and private equity to invest in an underserved sector: women's and children's health technology.

The firm was founded on the idea that borders should not dictate who gets access to the best health technologies, and plays an important role in the health technology market by investing in companies

that are creating innovations that have the potential to save lives or transform healthcare in North America, Europe and emerging markets.

While CBIV officially announced Fund I in late 2021, CBIV initially began fundraising for it a week before COVID-19 rocked the world. The final close in November 2023 marked the end of a challenging journey. Despite the pandemic, economic downturn, and various shifts in impact investment priorities in recent years, CBIV was still able to secure a sizeable amount of \$90M by its final close, especially for an women-led emerging manager and first-time fund.

To date, CBIV has made 9 investments to date across the US and Europe, and aims to be fully allocated for Fund I by the Fall of 2025. It is targeting \$125M for Fund II, and hopes to achieve its first close by November 2025.

words remaining :

217

History of the development of the fund / Incubators

(please be as specific as possible in your description; limit 500 words)

Similarly to Fund I, Cross-Border Impact Ventures' Women's and Children's Health Technology Fund II will invest in Series A/B health companies in early revenues (typically less than \$10M USD) commercializing medical devices, diagnostic tools, digital therapeutics, and digital health solutions and leveraging cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML). The Fund's mission is to contribute to addressing the unmet health needs of women and children, now including healthcare needs exacerbated by climate change. Most prospective portfolio investments are based in the U.S. and Europe where strong investment performance can be achieved more predictably. The Fund's areas of focus have been defined for women and children as areas that affect women specifically, differently or disproportionately and for children, CBIV adds areas where no medical products have been validated for young populations as the need is great for tailored evidence-based solutions.

We are driven by our belief that good health should not be restricted by gender, age, race, wealth, or borders and seek to expand access to our portfolio's world class technologies inclusively and globally.

words remaining :

324

*Kindly clearly label your files with company name and asset name.

Attached Files:

- [CBIV Fund II Short Deck 2025_05192025.pdf](#)
- [CBIV Fund 2 General 1 Pager_05122025.pdf](#)

How do you address your portfolio needs *

(please be as specific as possible in your description; 500 words)

Our investees - CEOs of prospective companies - and early-stage investors confirm that we bring a unique value proposition that they view as desirable to push the bar for global growth. Our focused approach and network often makes us the most knowledgeable voice at the board table and on the cap table. Investees see opportunity in our unique investment strategy and access to our broad network of experts in health and non-dilutive funders who can support these strategies. They value

our decades of expertise in venture capital, private equity and lending, combined with the decades of operating and scientific experience of our 25+ advisors specialized in our areas of interest.

We are hands-on investors who take active positions on the board to improve commercial growth and health impact and can lead or co-lead deals. We also work closely with our companies after investing to encourage gender diversity and good governance. Whether it's assisting our portfolio companies with their fundraising strategies or playing a key role in helping them to carefully consider their capital structure in creative ways that are bound to attract investors and funders within the health space, Cross-Border Impact Ventures is a master of encouraging others to thrive.

words remaining :

300

Impact / Metrics to measure Success *

Other than targeting venture capital returns typical for the medtech industry, CBIV's success is primarily measured by the number of women, children, and adolescents who gain access to improved health outcomes through its portfolio companies. This is tracked using three core KPIs:

- Lives Saved
- Lives Improved
- Lives Accessed

These KPIs are forecasted over a 10-year horizon and are grounded in clinical evidence, company data, and scientific literature. To date, CBIV's portfolio has reached over 276K people globally, with a forecasted reach of 51M people.

Why your model is innovative, and/or how it will improve the human condition *

There are a multitude of impact investment funds which, by definition, work to create positive social outcomes and generate financial returns. There are also many traditional for-profit healthcare venture funds that aim to drive new developments in healthcare. Historically, however, there are few funds that combine social impact, financial returns and health innovation. In part because of this, relatively few health products and services are developed for and targeted to underserved populations, creating a powerful need that does not receive adequate attention or resources.

Enter CBIV. CBIV sits at the nexus of impact investing and health innovation with the explicit goal of catalyzing essential investment in the health impact space and improving the lives of 8 million women and children while doing so.

CBIV is intent on showcasing that it is possible to do well while doing good. CBIV is changing the way investors view reaching underserved populations around the world with the newest and most effective health technologies within their portfolios, with emphasis on women, children and adolescents. We do this by investing in novel technology solutions that are, among other things, cost effective, easier to use by health practitioners, more convenient - and/or less painful for patients - and, most importantly, will have a material health outcome improvement on their lives.

words remaining :

287

Please provide appropriate references (PubMed, Abstract, Website) *

Cross-Border Impact Ventures video: <https://www.youtube.com/watch?v=NOLGLkSZxwU>

Cross-Border Impact Ventures website: <https://www.crossborder.ventures/>

Cross-Border Impact Ventures media coverage book:
<https://boulevardpr.coveragebook.com/b/5c14ef50cce49d17>

Cross-Border Impact Ventures Linkedin: <https://ca.linkedin.com/company/cross-border-impact-ventures>